TCR trials were conducted for non-melanoma malignancies targeting the cancer-testis antigen NY-ESO-1 [18], the onco-fetal carcinoembryonic antigen CEA for colorectal cancer [19], or melanoma antigen-encoding genes (MAGEs) [20]. This evidence concerns the gene CEACAM5 and melanoma.